Skip to primary content
Skip to secondary content

Biotech 365

Main menu

  • Biotech 365
  • Companies
  • Healthcare Investors
    • Healthcare LPs
  • Healthcare Investors Matchmaking
  • Free DEMO
  • Services
    • Preclinical Studies Database
    • Scientific Due Diligence
    • CRO & CDMO Database
  • Contact

Tag Archives: PBC

Intercept Pharma – bile acid therapeutics

Posted on by

Intercept Pharma is a biopharma company focused on the development of novel therapeutics to treat chronic liver diseases utilizing its proprietary bile acid chemistry.

Intercept Pharma – bile acid therapeutics

Intercept Pharma Continue reading →

Posted in Biotech Companies, Biotech Companies USA | Tagged anticholestatic, antifibrotic, Barbara Duncan, bile acid, bile acid therapeutics, cholestatic liver disease, chronic liver disease, chronic liver diseases, David Shapiro, farnesoid, farnesoid X receptor, FXR, FXR agonism, Glenn Sblendorio, GLP-1, glucagon-like peptide-1, INT-767, INT-777, Intercept Pharma, Intercept Pharma - bile acid therapeutics, Intercept Pharmaceuticals, Jonathan Silverstein, Klaus Veitinger, Luca Benatti, Luciano Adorini, Mark Pruzanski, NASH, Nicole Williams, Nonalcoholic steatohepatitis, Obeticholic acid, OCA, Paolo Fundarò, PBC, Primary Biliary Cirrhosis, Primary sclerosing cholangitis, PSC, Rachel McMinn, Sanj Patel, Srinivas Akkaraju, TGR5, TGR5 agonist

        Services              Healthcare Investors Database              FAQs               CGU               Biotech & Pharma News             Contact
Proudly powered by WordPress